Cariprazine (RGH-188) is a novel
antipsychotic drug that exerts partial agonism of
dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Currently,
cariprazine is in late-stage clinical development (phase III clinical trials) in patients with
schizophrenia (S) and in patients with
bipolar disorder (BD), as well as an adjunctive treatment in patients with
Major Depressive Disorder (MDD) and drug-resistant MDD.
Cariprazine has completed phase III trials for the acute treatment of
schizophrenia and bipolar
mania, phase II trials for the
bipolar depression and MDD whilst it is undergoing phase III trials as an adjunct to
antidepressants. The present review aims at proving a comprehensive summary of the current evidence on the safety, tolerability and efficacy of
cariprazine in the treatment of
schizophrenia, BD (manic/mixed/ depressive episode) and MDD. A systematic search was conducted on PubMed/Medline/ Scopus and the database on Clinical Trials from inception until April 2015 by typing a set of specified keywords. Available evidence seems to support
cariprazine efficacy in the treatment of cognitive and negative symptoms of
schizophrenia. Preliminary findings suggest its antimanic activity whilst it is still under investigation its efficacy in the treatment of
bipolar depression and MDD. Furthermore, the available data seems not to allow judgements about its
antipsychotic potential in comparison with currently prescribed
antipsychotics. Further studies should be carried out to better investigate its pharmacodynamic and clinical potential, particularly as alternative to current
antipsychotic drugs.